| Recruiting | Pancreatic Cancer Diagnosis With FAPI-PET Imaging NCT07098598 | Turku University Hospital | Phase 2 / Phase 3 |
| Unknown | Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer NCT04902261 | Changhai Hospital | Phase 2 |
| Completed | Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic NCT02153450 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Withdrawn | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Tr NCT02048943 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian NCT01927393 | City of Hope Medical Center | N/A |
| Completed | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255 | Wake Forest University Health Sciences | Phase 1 |
| Withdrawn | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liv NCT01741597 | City of Hope Medical Center | Phase 1 |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Completed | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer NCT01924260 | Edward Kim | Phase 1 |
| Completed | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT01839981 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic NCT01821612 | Alliance for Clinical Trials in Oncology | EARLY_Phase 1 |
| Completed | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer NCT01835041 | Wake Forest University Health Sciences | Phase 1 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer NCT01666730 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors NCT01525082 | Shaheen Shagufta | Phase 2 |
| Completed | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer NCT01473940 | Northwestern University | Phase 1 |
| Completed | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Can NCT01537107 | Mayo Clinic | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer NCT01191684 | City of Hope Medical Center | Phase 1 |
| Completed | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreati NCT01234935 | Translational Oncology Research International | Phase 2 |
| Terminated | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer NCT01227018 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT01222689 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer NCT01232829 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tum NCT01145456 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Ca NCT00981162 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer NCT00735917 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer NCT00577889 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery NCT00482625 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer NCT00474812 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors NCT00462553 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With NCT00397787 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer P NCT00383760 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer NCT00331682 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00095966 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer NCT00085371 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pan NCT00091026 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT00088894 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00075647 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreat NCT00063947 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Ad NCT00047307 | National Cancer Institute (NCI) | Phase 1 |
| Completed | UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer NCT00039403 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer NCT00031694 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer NCT00028834 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer NCT00019006 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Panc NCT00253526 | National Cancer Institute (NCI) | Phase 2 |